B. Braun Medical Heparin Injection Recall: Subpotent Drug Risk
B. Braun Medical recalls heparin sodium injection with low anti-Factor IIa potency. This may cause ineffective blood clotting. Affected lots: J2C017, expires 9/30/2023.
Lower-risk recall
Subpotent Drug: low Anti-Factor IIa potency.
Contact the company
What happened, in plain English
B. Braun Medical is recalling heparin sodium injection due to low anti-Factor IIa potency. This means the medication may not work properly to prevent blood clots, risking ineffective treatment. Read more at govinfonow.com/recall/33836-b-braun-medical-heparin-injection-recall-subpotent-drug-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/33836-b-braun-medical-heparin-injection-recall-subpotent-drug-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0434-2023
Cite this page
“B. Braun Medical Heparin Injection Recall: Subpotent Drug Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/33836-b-braun-medical-heparin-injection-recall-subpotent-drug-risk. Based on FDA recall #D-0434-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0434-2023%22&limit=1).
Why it’s dangerous
The heparin has lower-than-stated anti-Factor IIa potency, meaning it may not work effectively to prevent blood clots. This could lead to complications like blood clots forming in the body when the medication is supposed to prevent them.
Who’s affected
Healthcare professionals using this heparin injection for blood clot prevention. Patients receiving treatment with this specific product are at risk of ineffective clot management.
How to tell if you have this one
Check for the Excel container with 250 mL of 5% Dextrose Injection. The lot number J2C017 and expiration date 9/30/2023 are specific identifiers for this recall.
- Brand
B. Braun Medical- Category
Drug
What to do — step by step
Check Product Details
Look for the Excel container with 250 mL of 5% Dextrose Injection, lot number J2C017, and expiration date 9/30/2023.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 12 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0434-2023 (March 1, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0434-2023 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.